Oxford BioMedical 2017/2018 lentiviral vector capacity expansion project

Oxford BioMedica (OXB) is a company with broad and global market-leading capabilities in terms of development, manufacture and testing of lentiviral vectors for clinical and commercial use. As a platform/product developer OXB pioneered in vivo delivery of lentiviral vectors, and we have several strategic partnerships, such as one with Novartis supporting the development of chimeric antigen receptor (CAR)-T-cell programmes, including Kymriah™ which is the only commercially approved product based on lentiviral vector technology. OXB seeks funding in support of a £6m project to help expand our existing GMP manufacturing capacity in the UK. This project is linked into a broader capacity expansion plan that will lead to increased high value manufacturing activities, together with the commitment to create many more highly skilled jobs. OXB continues to develop technologies based on state-of-the-art platform, manufacturing and testing capabilities, and will use the requested funding to further support our market leading position, ensuring the UK continues to lead in many areas of the development of advanced therapies.